14 January 2009: NorDiag will today start a roadshow for its planned public offering, with subscription period scheduled from January 16 to January 30 2009. Attached is the roadshow presentation.

Both the Rights Issue and the transaction details outlined in the presentation are conditional on Oslo Børs` approval of forwarded prospectus.

Contact:             
CEO Mårten Wigstøl      
Phone: +47 911 65 775
or morten.wigstol@nordiag.com
                         
CFO Tone Kvåle             
Phone: + 47 915 19 576
or tone.kvaale@nordiag.com

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Find the presentation here

Read the notice in Norwegian here